Stock Market Reviews

BIO (Bio-Rad Laboratories, Inc.) News

Get the latest news, insights, and market updates on BIO (Bio-Rad Laboratories, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Envista (NVST) Earnings Expected to Grow: Should You Buy?
  Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 23, 2025 - $BIO
• A Look at Bio-Rad Laboratories’s Valuation Following Expanded Biodesix Partnership in Cancer Diagnostics
  Bio-Rad Laboratories (BIO) has expanded its collaboration with Biodesix, aiming to clinically validate and pursue regulatory approval for cancer biomarker diagnostic assays. The partnership highlights the ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer. See our latest analysis for Bio-Rad Laboratories. Bio-Rad Laboratories’ move to deepen its partnership with Biodesix comes at a time when momentum appears to be shifting. Following the announcement, the company’s share price...
  Oct 23, 2025 - $BIO
• Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
  Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 22, 2025 - $BIO
• Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
  Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testingLOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic
  Oct 22, 2025 - $BIO
• Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
  HERCULES, Calif., October 16, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.
  Oct 16, 2025 - $BIO
• Aurora Cannabis (ACB) Soars 6.2%: Is Further Upside Left in the Stock?
  Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Oct 8, 2025 - $BIO
• Multi-Plex Immunoassays Market to Reach US$ 6.90 Billion by 2033 as Precision Medicine and Biomarker Discovery Fuel Global Adoption | DataM Intelligence
  The Multi-Plex Immunoassays Market is entering a new era of growth as clinical diagnostics, drug discovery, and personalized medicine increasingly rely on high-throughput, multi-analyte testing platforms. According to DataM Intelligence, the Multi-Plex Immunoassays Market Size stood at US$ 3.32 billion in 2024 and is projected to expand to US$ 6.90 billion by 2033, growing at a CAGR of 8.5% during 2025–2033.
  Oct 7, 2025 - $BIO
• Bio-Rad Laboratories (BIO): Is the Current Valuation Justified After Recent Share Price Uptick?
  Bio-Rad Laboratories (BIO) has seen its stock edge upward over the past week, catching some attention among investors. Shares closed at $297.95, reflecting modest gains that contrast with longer-term declines. See our latest analysis for Bio-Rad Laboratories. Taking a step back, Bio-Rad Laboratories’ 1-year total shareholder return is modestly negative. This highlights how recent share price strength comes after a longer stretch of muted momentum. While the stock has eked out a slight gain...
  Oct 2, 2025 - $BIO
• GCC Liquid Biopsy Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Bio-Rad, Thermo Fisher Scientific, Johnson & Johnson, Guardant Health, QIAGEN, Sysmex
  The GCC Liquid Biopsy Market is projected to grow from US$ 98.24 million in 2024 to US$ 309.53 million by 2033, at a CAGR of 13.60%. This rapid growth is driven by rising cancer incidence, advances in genomics technology, increased healthcare spending, and government support for precision medicine. Liquid biopsies offer a non-invasive alternative to tissue biopsies, allowing for early cancer detection and personalized treatment. Despite challenges like high costs and regulatory hurdles, the mark
  Oct 1, 2025 - $BIO
• Investors in Bio-Rad Laboratories (NYSE:BIO) have unfortunately lost 47% over the last five years
  While it may not be enough for some shareholders, we think it is good to see the Bio-Rad Laboratories, Inc. ( NYSE:BIO...
  Oct 1, 2025 - $BIO